Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carfilzomib
Drug ID BADD_D00367
Description Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Indications and Usage Carfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate.
Marketing Status Prescription
ATC Code L01XG02
DrugBank ID DB08889
KEGG ID D08880
MeSH ID C524865
PubChem ID 11556711
TTD Drug ID D00UVA
NDC Product Code 50384-0180; 52076-6251; 76075-103; 50384-0230; 54893-0037; 76055-0035; 63552-009; 16436-0116; 63552-035; 50384-0260; 55111-985; 11722-059; 50384-0220; 50384-0210; 50384-0190; 67262-0010; 76075-102; 50384-0240; 42385-731; 76075-101
Synonyms carfilzomib | PR-171 | PR171 | Kyprolis
Chemical Information
Molecular Formula C40H57N5O7
CAS Registry Number 868540-17-4
SMILES CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3) NC(=O)CN4CCOCC4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gait disturbance17.02.05.016; 08.01.02.0020.007726%
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis viral11.05.04.005; 07.19.03.0050.000533%Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Generalised oedema14.05.06.007; 08.01.07.0040.000533%
Generalised tonic-clonic seizure17.12.01.002--Not Available
Gingival bleeding07.09.07.001; 24.07.02.010--Not Available
Glycosylated haemoglobin increased13.02.02.0050.000533%Not Available
Gout15.01.06.001; 14.09.01.001--Not Available
Graft versus host disease10.02.01.027; 12.02.09.0010.000139%Not Available
Groin pain15.03.02.0040.000533%Not Available
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematochezia24.07.02.012; 07.12.02.003--Not Available
Haematocrit decreased13.01.05.0010.000799%Not Available
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin abnormal13.01.05.0110.001332%Not Available
Haemoglobin decreased13.01.05.0030.009058%Not Available
Haemolysis01.06.04.0020.002398%
Haemolytic anaemia01.06.03.0020.004795%Not Available
Haemolytic uraemic syndrome01.06.02.001; 20.01.03.0110.002131%
Haemoptysis02.01.02.006; 24.07.01.006; 22.02.03.004--Not Available
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
Haemorrhagic stroke24.07.04.014; 17.08.01.011--Not Available
Hair colour changes23.02.06.0010.000533%
Hallucination19.10.02.002--
Head discomfort17.02.05.0270.001066%Not Available
Headache17.14.01.001--
Heart rate increased13.14.04.0020.003730%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 18 Pages